Antihyperlipidemic Drugs Market - Global Industry Analysis

Antihyperlipidemic Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2028

Category: Pharmaceutical Report Format : PDF Report Code: ZMR-6851 Status : Upcoming

Description

Global Antihyperlipidemic Drugs Market: Overview

Hyperlipidemia also referred to as hyperlipoproteinemia, is a lipid condition characterized by elevated lipid (fat) levels in the blood. It's caused by a problem with lipid metabolism, a problem with plasma lipoprotein production & breakdown, or a plasma lipid transport. Hyperlipidemia is a serious medical problem that must be addressed. Lipid-lowering medications also called cholesterol-lowering, or antihyperlipidemic drugs, are a class of drugs that are used to lower high blood levels of lipids (fats) and lipoproteins (fats containing protein). These medicines are meant to treat cardiovascular disorders such as atherosclerosis and reduce the risk of heart attacks.

Report Scope:

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Global Antihyperlipidemic Drugs Market: Growth Factors

The global antihyperlipidemic drugs market is fueling at a speedy rate. The prime factor contributing to the growth of the market is the rise in cases of hyperlipidemia and cardiovascular diseases. CVD is the world's leading cause of mortality. In 2019, 17.9 million individuals died from cardiovascular disease (CVD), accounting for 32% of all deaths worldwide. Heart attacks and strokes were responsible for 85 percent of these fatalities. CVD is also the biggest cause of mortality in Europe, responsible for 47 percent of women's deaths and 39 percent of men's deaths. Furthermore, according to a survey by faculty members at the University Putra Malaysia's Department of Nutrition and Health Sciences, cardiovascular diseases are anticipated to cause seven out of every ten fatalities in developing countries by 2020. This is leading to the huge demand for antihyperlipidemic drugs, thereby driving the market growth. In addition to this, an increase in sedentary lifestyle, rise in healthcare expenditure, and rise in geriatric population are also some of the key factors that are driving the global market. Furthermore, in the near future, significant research and development of antihyperlipidemic combination drugs is expected to boost the global antihyperlipidemic drugs market. However, the increased cost of therapy, as well as strict government rules and laws around medication patents, may limit the global antihyperlipidemic drugs market growth.

COVID-19 was formerly assumed to be a virus that only affected the lungs, but it has now been shown that it may also affect and damage the heart, posing a higher risk of consequences for the many individuals worldwide who already have or are at risk of heart disease. Cardiovascular problems are common in COVID-19 patients, and these, together with pre-existing cardiovascular comorbidities and RF, may lead to severe clinical outcomes and death. Clinicians all across the globe should be aware of this link in order to identify patients who are at higher risk. In the projection period, the increased prevalence of illness among CVD patients would fuel the rise of antihyperlipidemic drugs.

Global Antihyperlipidemic Drugs Market: Segmentation

The global antihyperlipidemic drugs market is bifurcated based on the route of administration, drug class, distribution channel, and region. Based on the route of administration, the global market is divided into intravenous and oral. Cholesterol absorption inhibitors, bile acid sequestrants, statins, combination, PCSK9 inhibitors, and fibric acid derivatives are the drug class of antihyperlipidemic drugs. The distribution channel segment is classified into online retailers, retail stores, and hospital pharmacies.

Global Antihyperlipidemic Drugs Market: Regional Analysis

In terms of revenue, North America is anticipated to lead the global antihyperlipidemic drugs market, and this trend is expected to continue over the projected period. The market for antihyperlipidemic drugs in North America is expected to grow as the frequency of vascular disorders and the number of amputations in the area rise. North American market expansion may also be ascribed to significant expenditures in R&D and healthcare spending by governments and commercial companies in the prosthetics industry in the area. In terms of market share for antihyperlipidemic drugs, Europe is expected to hold the second position in the market. This is owing to mandatory medical insurance in nations like France and Germany, as well as significant disposable income and considerable R&D activity in the region's healthcare industry.

Global Antihyperlipidemic Drugs Market: Competitive Players

Biotest AG, Shire Plc, Pfizer, Inc., Grifols S.A., AstraZeneca plc, Talecris Biotherapeutics, Inc, Baxalta Incorporated, Kedrion S.p.A., Octapharma AG, and Boehringer Ingelheim GmbH are the dominating players that are functioning in the global antihyperlipidemic drugs market.

Global Antihyperlipidemic Drugs Market: Regional Segment Analysis

  • North America
    • The U.S.
    • Canada
  • Europe
    • France 
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

What Reports Provides

  • Full in-depth analysis of the parent market
  • Important changes in market dynamics
  • Segmentation details of the market
  • Former, on-going, and projected market analysis in terms of volume and value
  • Assessment of niche industry developments
  • Market share analysis
  • Key strategies of major players
  • Emerging segments and regional markets
  • Testimonials to companies in order to fortify their foothold in the market.

 

Table Of Content

Choose License Type

Request the coronavirus impact analysis across industries and markets

FrequentlyAsked Questions

The global antihyperlipidemic drugs market is fueling at a speedy rate. The prime factor contributing to the growth of the market is a rise in cases of hyperlipidemia and cardiovascular diseases.  In addition to this, an increase in sedentary lifestyle, rise in healthcare expenditure, and rise in geriatric population are also some of the key factors that are driving the global market. Furthermore, in the near future, significant research and development of antihyperlipidemic combination drugs is expected to boost the global antihyperlipidemic drugs market.

Biotest AG, Shire Plc, Pfizer, Inc., Grifols S.A., AstraZeneca plc, Talecris Biotherapeutics, Inc, Baxalta Incorporated, Kedrion S.p.A., Octapharma AG, and Boehringer Ingelheim GmbH are the dominating players that are functioning in the global antihyperlipidemic drugs market.

In terms of revenue, North America is anticipated to lead the global antihyperlipidemic drugs market, and this trend is expected to continue over the projected period. The market for antihyperlipidemic drugs in North America is expected to grow as the frequency of vascular disorders and the number of amputations in the area rise.

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed